Picture of Altimmune logo

ALT Altimmune Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapHigh Flyer

Momentum

Relative Strength (%)
1m+7.36%
3m-10.65%
6m+188.29%
1yr+64.41%
Volume Change (%)
10d/3m-55.03%
Price vs... (%)
52w High-38.81%
50d MA-10.36%
200d MA+65.94%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)n/a
PEG Ratio (f)n/a
EPS Growth (f)n/a
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value3.24
Price to Tang. Book3.54
Price to Free Cashflown/a
Price to Sales1,748.6
EV to EBITDAn/a

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-55.2%
Return on Equity-44.15%
Operating Margin-30609.32%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202331st Dec 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Altimmune EPS forecast chart

Profile Summary

Altimmune, Inc. is a clinical-stage biopharmaceutical company that is focused on developing treatments for obesity and liver diseases. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). It is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The Company has initiated a Phase II clinical trial of HepTcell and is in Phase II and Phase I clinical development with pemvidutide for multiple indications. It is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany Spain and Thailand. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Directors

Last Annual
December 31st, 2022
Last Interim
September 30th, 2023
Incorporated
April 25th, 2005
Public Since
October 6th, 2005
No. of Shareholders
178
No. of Employees
52
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
53,728,871

ALT Share Price Performance

Upcoming Events for ALT

Q4 2023 Altimmune Inc Earnings Call

Q4 2023 Altimmune Inc Earnings Release

Q1 2024 Altimmune Inc Earnings Release

Altimmune Inc GLP-1-Based Therapeutics Summit

Q2 2024 Altimmune Inc Earnings Release

Similar to ALT

Picture of 89bio logo

89bio

us flag iconNASDAQ Global Market

Picture of Abivax SA logo

Abivax SA

us flag iconNASDAQ Global Market

Picture of AC Immune SA logo

AC Immune SA

us flag iconNASDAQ Global Market

Picture of Acrivon Therapeutics logo

Acrivon Therapeutics

us flag iconNASDAQ Global Market

Picture of Adagene logo

Adagene

us flag iconNASDAQ Global Market

FAQ